Furthermore, it has been well confirmed that EZH2 is extensively overexpressed and is associated with more aggressive behavior and poor prognosis in a wide range of cancer types, including prostate cancer, breast cancer, melanoma, and non-small cell lung carcinoma [14–18]. This evidence concerns the gene EZH2 and Familial prostate cancer.